Comparing one vs. multiple nasal treatments in NICU babies
Part of Infections clinical trials.
This study tests whether giving one versus multiple doses of a special nasal treatment (called nasal microbiota therapy, or NMT) changes the types of helpful bacteria in your baby's nose. The goal is to see if the treatment keeps bad bacteria, like staph, from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be in the NICU for at least 7 days.
- Your baby must be at least 25 weeks old (from when you got pregnant).
- You (the parent or guardian) must not have staph bacteria (Staphylococcus aureus) in your nose.
- Your baby must not have staph bacteria in their nose.
- You must be able to give written permission for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a nasal spray of healthy bacteria to infants can restore good germs in the nose after they receive mupirocin ointment to treat Staph aureus. It aims to bring back a healthy nasal microbiome.
This trial tests a new nose spray called HY-133 to see if it's safe and can clear a common type of staph bacteria from the nose. It is for people who have this bacteria but not the antibiotic-resistant kind.
This study looks at the bacteria in the nose and throat of children and young adults who have a respiratory infection. It aims to understand how these bacteria might affect the infection and recovery.
This study looks at how newborns’ bodies are affected by COVID-19 around birth and whether a breathing support treatment (inhaled nitric oxide) changes outcomes. It also compares COVID-exposed babies and a similar group of babies without COVID who are not receiving the breathing treatment.
This study looks at how antibiotics affect MRSA (a type of staph infection) in the noses of hospitalized children. It may help doctors better understand MRSA to improve treatment.
This trial studies the bacteria living in the nose of patients with a staph bloodstream infection. It aims to better understand why some infections persist, which could lead to better treatments.
Hear when a new Staphylococcus Aureus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.